Condition: Liver Cirrhosis · Sarcopenia · Sponsor: Lipocine Inc.
This is a randomized, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of LPCN 1148 in men with cirrhosis of the liver and sarcopenia.
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| Mayo Clinic | Scottsdale, Arizona, United States | — |
| University of California, Los Angeles | Los Angeles, California, United States | — |
| University of California San Francisco | San Francisco, California, United States | — |
| University of Maryland Medical Center | Baltimore, Maryland, United States | — |
| Beth Israel Deaconess Medical Center | Boston, Massachusetts, United States | — |
| Methodist Health System | Dallas, Texas, United States | — |
| University of Texas Southwestern | Dallas, Texas, United States | — |
| Mt.Olympus Medical Research | Houston, Texas, United States | — |
| Intermountain Healthcare | Murray, Utah, United States | — |
| University of Utah | Salt Lake City, Utah, United States | — |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04874350